日报更新时间：04-10 10:00
周报更新时间：04-11 03:39
今开价：33.4
最高价：33.56
成交量：2717737.0
昨收价：33.49
最低价：31.74
最新价：32.16
中文名称：太平洋生物科学
英文名称：Pacific Biosciences of California
简介：Pacific Biosciences of California, Inc.在2000成立于特拉华州
电话：1-650-5218000
Pacific Biosciences of California, Inc.的成立，是建立在康奈尔大学的研究成果上——结合半导体工艺和光子学与生物技术研究，成立之初名为Nanofluidics, Inc.，经过6轮融资，获得4亿美金的风投资金，使公司成为2010年初创公司中的明星企业，同年10月，公司IPO登陆纳斯达克，主要的投资者包括：Mohr Davidow Ventures、Perkins、Wellcome Trust、Kleiner、Caufield & Byers、Alloy Ventures等。加州太平洋生物科学公司主要设计、开发、制造及销售用于基因分析的整合平台，是一家基因测序系统开发和制造公司。Pacific Biosciences of California公司提供单分子实时(SMRT)技术平台，使单分子能够即时侦测生物过程；PacBio RS II高解析度基因分析仪，可即时传导、监测与分析单分子生物化学反应。加州太平洋生物科学公司提供的消耗品部份，包括：密封包装SMRT细胞以及各种试剂套组，如：样品制剂套组、结合试剂套组，以及进行PacBio RS II定序套组等。Pacific Biosciences of California公司的客户包括研究机构、商业实验室、基因体中心、临床、政府与学术机构、基因体学服务提供者、制药公司及农业公司，其产品主要通过直销团队在北美及欧洲销售，亚洲主要为通过经销商销售。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-03-14 | Phillips (James Michael) | Officer | Buy | 7500 | -- |
| 2019-02-18 | Barnes (Susan K) | Chief Financial Officer | Sell | 11987 | 7.16 |
| 2019-02-18 | Phillips (James Michael) | Officer | Sell | 7231 | 7.17 |
| 2019-02-18 | Ordonez (Kathleen P) | Director | Sell | 6933 | 7.17 |
| 2019-02-18 | Hunkapiller (Michael W) | Chief Executive Officer | Sell | 13335 | 7.19 |
| 2019-02-14 | Barnes (Susan K) | Chief Financial Officer | Buy | 21250 | -- |
| 2019-02-14 | Ordonez (Kathleen P) | Director | Buy | 19950 | -- |
| 2019-02-14 | Barnes (Susan K) | Chief Financial Officer | Buy | 19950 | -- |
| 2019-02-14 | Hunkapiller (Michael W) | Chief Executive Officer | Buy | 22800 | -- |
| 2019-02-14 | Hunkapiller (Michael W) | Chief Executive Officer | Buy | 38750 | -- |
| 2019-02-14 | Phillips (James Michael) | Officer | Buy | 8000 | -- |
| 2019-02-14 | Phillips (James Michael) | Officer | Buy | 13605 | -- |
| 2018-12-19 | Barnes (Susan K) | Chief Financial Officer | Buy | 18228 | 2.63 |
| 2018-12-19 | Barnes (Susan K) | Chief Financial Officer | Buy | 48762 | 2.27 |
| 2018-12-19 | Barnes (Susan K) | Chief Financial Officer | Buy | 250000 | 4.79 |
| 2018-11-26 | Ordonez (Kathleen P) | Officer and Director | Buy | 25000 | 2.90 |
| 2018-11-26 | Ordonez (Kathleen P) | Officer and Director | Sell | 25000 | 7.54 |
| 2018-08-31 | Phillips (James Michael) | Officer | Buy | 1 | 2.01 |
| 2018-03-14 | Ordonez (Kathleen P) | Officer and Director | Buy | 43750 | -- |
| 2018-03-14 | Hunkapiller (Michael W) | Chief Executive Officer | Buy | 50000 | -- |
| 2018-03-14 | Barnes (Susan K) | Chief Financial Officer | Buy | 43750 | -- |
| 2018-02-28 | Phillips (James Michael) | Officer | Buy | 5989 | 2.01 |
| 2018-02-14 | Phillips (James Michael) | Officer | Buy | 15000 | -- |
| 2017-11-23 | Corcoran (Kevin P) | Officer | Buy | 256 | 1.96 |
| 2017-08-31 | Phillips (James Michael) | Officer | Buy | 3244 | 4.07 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Marshall Wace Asset Management Ltd | 1914428 | 1.25% | 1294427 | 208.78% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 3873183 | 2.54% | -156 | -- | 2019-07-31 |
| BlackRock Fund Advisors | 6063773 | 3.97% | -346615 | -5.41% | 2019-07-31 |
| Eckert Corp | 6072459 | 3.98% | 1814941 | 42.63% | 2019-03-31 |
| Cnh Partners, LLC | 6751127 | 4.42% | 166229 | 2.52% | 2019-03-31 |
| Water Island Capital LLC | 7247354 | 4.75% | 5882823 | 431.12% | 2019-03-31 |
| Vanguard Group Inc | 7611207 | 4.99% | 154082 | 2.07% | 2019-03-31 |
| Magnetar Financial LLC | 8217938 | 5.38% | -1064739 | -11.47% | 2019-03-31 |
| BlackRock Inc | 11138603 | 7.30% | -117727 | -1.05% | 2019-03-31 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 3383284 | 2.22% | -79008 | -2.28% | 2019-03-31 |
| ARP AMERICAS LLC | 3117632 | 2.04% | 2103200 | 207.33% | 2019-03-31 |
| Gabelli Funds LLC | 2900106 | 1.90% | 1155636 | 66.25% | 2019-03-31 |
| LMR Partners LLP | 1980650 | 1.30% | 155650 | 8.53% | 2019-03-31 |
| Citigroup Inc | 2248523 | 1.47% | 632464 | 39.14% | 2019-03-31 |
| Blackstone Group Inc | 2411556 | 1.58% | -- | -- | 2019-03-31 |
| Citadel Advisors Llc | 2646665 | 1.73% | 2626918 | 13302.87% | 2019-03-31 |
| Millennium Management LLC | 2730462 | 1.79% | 64374 | 2.41% | 2019-03-31 |
| Northern Trust Investments Inc | 2743086 | 1.80% | 40425 | 1.50% | 2019-07-31 |
| State Street Corporation | 2759036 | 1.81% | 156705 | 6.02% | 2019-03-31 |
| Goldman Sachs Group Inc | 2859483 | 1.87% | 204228 | 7.69% | 2019-03-31 |
| Blackstone Group LP | 2411556 | 1.58% | -- | -- | 2019-03-31 |
| BlackRock Asset Management Canada Ltd | 3216337 | 2.11% | -210 | -0.01% | 2019-05-31 |
| Geode Capital Management, LLC | 3146962 | 2.06% | 1729885 | 122.07% | 2018-12-31 |
| Oracle Investment Management Inc | 2557764 | 1.68% | -6829870 | -72.75% | 2018-12-31 |
| UBS Group AG | 1919173 | 1.26% | 1428246 | 290.93% | 2018-12-31 |
| Capital Research & Mgmt Co - Division 3 | 2080000 | 1.36% | -2082441 | -50.03% | 2018-12-31 |
| Consonance Capital Management LP | 2455114 | 1.61% | -11057844 | -81.83% | 2018-12-31 |
| D. E. Shaw & Co LP | 2099833 | 1.38% | 1837321 | 699.90% | 2018-12-31 |
| Capital Research and Management Company | 2080000 | 1.38% | -6763303 | -76.48% | 2019-03-31 |
| Bellevue Group AG | 2575000 | 1.71% | 2575000 | -- | 2018-09-30 |
| Broadfin Capital, LLC | 2493021 | 1.65% | 1438930 | 136.51% | 2018-09-30 |
| Northern Trust Corp | 1526320 | 1.02% | 63090 | 4.31% | 2018-09-30 |
| Federated Investors Inc | 1600000 | 1.07% | 1600000 | -- | 2018-09-30 |
| RTW INVESTMENTS, LLC | 2237607 | 1.50% | 2237607 | -- | 2018-09-30 |
| Capital World Investors | 4680862 | 3.13% | -4696594 | -50.08% | 2018-09-30 |
| Point72 Asset Management, L.P. | 5175000 | 3.47% | 2275000 | 78.45% | 2018-09-30 |
| ARK Investment Management LLC | 7786485 | 5.21% | 1465192 | 23.18% | 2018-09-30 |
| Maverick Capital Ltd | 12173094 | 8.15% | -- | -- | 2018-09-30 |
| Larry N Feinberg | 4892337 | 3.28% | -624557 | -11.32% | 2017-12-31 |
| Federated Global Inv Mgmt Corp | 1600000 | 1.07% | 1600000 | -- | 2018-09-30 |
| Invesco Advisers, Inc. | 1966580 | 1.32% | -27925 | -1.40% | 2018-11-30 |
| BlackRock Institutional Trust Company NA | 3080389 | 2.07% | -16418 | -0.53% | 2018-06-30 |
| Federated Equity Mgmt Co. Of Penn | 1600000 | 1.07% | 1600000 | -- | 2018-11-30 |
| Raging Capital Management LLC | 3316614 | 2.23% | 125519 | 3.93% | 2018-03-31 |
| Northern Trust Investments N A | 1463230 | 0.98% | 140090 | 10.59% | 2018-06-30 |
| Charles Schwab Investment Management Inc | 614288 | 0.47% | 95551 | 18.42% | 2018-06-30 |
| Arrowpoint Asset Management, LLC | 4507794 | 3.42% | -258618 | -5.43% | 2018-06-30 |
| Seventh MDV Partners, LLC | 5598397 | 4.81% | -- | -- | 2017-12-31 |
| Invesco Ltd | 4176951 | 3.59% | -1146255 | -21.53% | 2017-12-29 |
| State Street Corp | 2247341 | 1.70% | 354804 | 18.75% | 2018-06-30 |
| Frontier Capital Management CO Inc | 1429505 | 1.08% | -23198 | -1.60% | 2018-06-30 |
| Trellus Management Company, LLC | 700000 | 0.53% | -75000 | -9.68% | 2018-06-30 |
| BNY Mellon Investment Management | 319608 | 0.24% | 39768 | 14.21% | 2018-06-30 |
| Teachers Advisors Inc | 1029585 | 0.78% | -- | -- | 2018-03-31 |
| Mutual Of America Capital Management LLC | 510472 | 0.44% | 28384 | 5.89% | 2017-12-31 |
| Foresite Capital Management III, LLC | 447520 | 0.38% | -702480 | -61.09% | 2017-12-31 |
| Invesco Advisers, Inc | 4125123 | 3.55% | -1007770 | -19.63% | 2017-12-31 |
| California Public Employees Retrmnt Sys | 457400 | 0.39% | -- | -- | 2017-09-30 |
| NORTH TIDE CAPITAL LLC | 1000000 | 0.86% | 1000000 | -- | 2017-09-30 |
| Lord, Abbett & Co LLC | 814484 | 0.70% | 221473 | 37.35% | 2017-09-30 |
| Soros Fund Management LLC | 670400 | 0.58% | 670400 | -- | 2017-09-30 |
| BlackRock Advisors LLC | 586306 | 0.50% | -342378 | -36.87% | 2017-11-30 |
| Bridger Management LLC | 4964123 | 5.36% | -218116 | -4.21% | 2016-09-30 |
| KPCB XI ASSOCIATES, LLC | 1522576 | 1.90% | -1794800 | -54.10% | 2015-12-31 |
| Peregrine Capital Management Inc | 974505 | 1.05% | 974505 | -- | 2016-09-30 |
| Ghost Tree Capital, LLC | 750000 | 0.81% | 750000 | -- | 2016-09-30 |
| Brook Byers | 3696654 | 2.00% | 23288920 | -- | 1999-11-30 |
| Michael Hunkapiller, Ph.D. | 4437246 | 2.00% | 27954650 | 0.10% | 1999-11-30 |
| Entities affiliated with Deerfield Management Company, L.P. | 5120771 | 2.00% | 32260857 | 0.10% | 1999-11-30 |
| William Ericson | 5598397 | 2.00% | 35269901 | 0.10% | 1999-11-30 |
| Entities affiliated with Maverick Capital Ltd. | 6459784 | 2.00% | 40696639 | 0.10% | 1999-11-30 |
| BlackRock Inc. | 7382305 | 2.00% | 46508522 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Gabelli ABC Fund | 1058700 | 0.69% | 258700 | 32.34% | 2019-03-31 |
| Vanguard Total Stock Market Index Fund | 3846277 | 2.51% | -- | -- | 2019-06-30 |
| iShares Russell 2000 ETF | 3105441 | 2.03% | 6083 | 0.20% | 2019-07-30 |
| Meridian Small Cap Growth Fund | 2098993 | 1.37% | -- | -- | 2019-03-31 |
| Arbitrage Fund | 2012969 | 1.32% | 610956 | 43.58% | 2019-05-31 |
| Vanguard Extended Market Index Fund | 1916461 | 1.25% | 4300 | 0.22% | 2019-06-30 |
| IQ Merger Arbitrage ETF | 1654931 | 1.08% | -- | -- | 2019-07-31 |
| iShares Nasdaq Biotechnology ETF | 1507141 | 0.99% | 15599 | 1.05% | 2019-07-30 |
| iShares Russell 2000 Growth ETF | 1196607 | 0.78% | 17740 | 1.50% | 2019-07-30 |
| Litman Gregory Masters Alt Strats Fund | 1019185 | 0.67% | 68902 | 7.25% | 2019-06-30 |
| Gabelli Entpr Mergers and AcquisitionsFd | 435000 | 0.28% | -- | -- | 2019-04-30 |
| GDL Fund | 450000 | 0.29% | 240000 | 114.29% | 2019-03-31 |
| NT R2000 Index Fund - NL | 531074 | 0.35% | 7633 | 1.46% | 2019-06-30 |
| Fidelity | 557810 | 0.36% | 69853 | 14.32% | 2019-04-30 |
| State Street Russell Small Cap | 572865 | 0.37% | -- | -- | 2019-06-30 |
| NT R2000 Growth Index Fund - Non-Lending | 581750 | 0.38% | -15677 | -2.62% | 2019-06-30 |
| State Street Russell Small/Mid Cap | 588114 | 0.38% | -- | -- | 2019-06-30 |
| iShares Healthcare Innov ETF | 592172 | 0.39% | -- | -- | 2019-07-30 |
| Vanguard Alternative Strategies Fund | 600000 | 0.39% | -- | -- | 2019-03-31 |
| Pictet TR - Divers Alpha | 1034138 | 0.68% | 647553 | 167.51% | 2019-05-31 |
| NT R2000 Growth Index Fund - Lending | 412974 | 0.27% | 10996 | 2.74% | 2019-03-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 2841593 | 1.86% | -4770 | -0.17% | 2019-05-30 |
| Vivaldi Merger Arbitrage Fund | 494620 | 0.32% | 494620 | -- | 2018-12-31 |
| American Funds SMALLCAP World Fund | 2080000 | 1.38% | -6763303 | -76.48% | 2018-12-31 |
| 1290 VT GAMCO Mergers & Acquisitions Ptf | 384011 | 0.25% | 84011 | 28.00% | 2019-01-31 |
| Schwab US Small-Cap ETF | 392885 | 0.26% | -- | -- | 2019-03-29 |
| Allianz Merger Arbitrage Strategy | 397147 | 0.26% | -- | -- | 2019-01-31 |
| Vanguard Health Care Index Fund | 358722 | 0.24% | 22380 | 6.65% | 2019-02-28 |
| Mutual of America Small Cap Value Fund | 355157 | 0.24% | -27404 | -7.16% | 2018-09-30 |
| Oppenheimer Global Multi-Alts Fd/VA | 342696 | 0.23% | -- | -- | 2019-01-31 |
| iShares Micro-Cap ETF | 335295 | 0.22% | -- | -- | 2019-02-28 |
| VA CollegeAmerica SMALLCAP Wld Fd | 2080000 | 1.38% | -6763303 | -76.48% | 2018-12-31 |
| Franklin K2 Alternative Strategies Fund | 278807 | 0.19% | -- | -- | 2018-12-31 |
| Bridgeway Ultra Small Company Market Fd | 320200 | 0.21% | -- | -- | 2018-09-30 |
| Schwab Small Cap Index Fund | 263830 | 0.18% | 29330 | 12.51% | 2018-12-31 |
| Victory RS Science and Technology Fund | 300000 | 0.20% | 300000 | -- | 2018-09-30 |
| Federated Kaufmann Small Cap Fund | 1600000 | 1.07% | 1600000 | -- | 2018-09-30 |
| OMI IM USD Franklin K2 Alt Strats | 278807 | 0.19% | 278807 | -- | 2018-11-30 |
| ArrowMark Small Cap Growth UCITS Fd | 201900 | 0.14% | -- | -- | 2018-11-30 |
| The Vanguard - Russell 2000 Grwth Idx CF | 217130 | 0.15% | -506 | -0.23% | 2018-11-30 |
| ARK Innovation ETF | 4219324 | 2.83% | -80020 | -1.86% | 2018-10-31 |
| ARK Genomic Revolution Multi-Sector ETF | 3308009 | 2.22% | 27411 | 0.84% | 2018-10-31 |
| TIAA-CREF Quant Small-Cap Equity Fund | 831700 | 0.56% | -- | -- | 2018-04-30 |
| BlackRock Advantage US Total Market Fund | 569285 | 0.38% | -25548 | -4.29% | 2017-09-30 |
| BrighthouseI Invesco Small Cap Gr Port | 824257 | 0.55% | -91208 | -9.96% | 2017-12-31 |
| Meridian Contrarian Fund | 1142477 | 0.77% | -130000 | -10.22% | 2017-09-30 |
| JNL/Invesco Small Cap Growth Fund | 1226249 | 0.82% | -66787 | -5.17% | 2017-12-31 |
| Invesco Small Cap Growth Fund | 1879430 | 1.26% | -115075 | -5.77% | 2017-12-31 |
| Fidelity Spartan | 502855 | 0.38% | -- | -- | 2018-07-31 |
| iShares Russell 2000 Growth | 1180329 | 0.87% | -1138 | -0.10% | 2018-09-12 |
| Vanguard Extended Market Idx Inv | 1513105 | 1.15% | -- | -- | 2018-07-31 |
| iShares Nasdaq Biotechnology | 1502139 | 1.11% | -2859 | -0.19% | 2018-09-12 |
| Meridian Small Cap Growth Investor | 2527597 | 1.92% | -59192 | -2.29% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 3334838 | 2.53% | -- | -- | 2018-07-31 |
| VA CollegeAmerica Smcap World 529E | 9377456 | 7.11% | -920621 | -8.94% | 2018-06-30 |
| Bridgeway Ultra-Small Company Market | 320200 | 0.24% | 145200 | 82.97% | 2018-06-30 |
| iShares Micro-Cap | 321916 | 0.24% | -- | -- | 2018-09-12 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 295117 | 0.22% | -136 | -0.05% | 2018-07-31 |
| CREF Stock R1 | 258916 | 0.20% | -5406 | -2.05% | 2018-07-31 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 275713 | 0.24% | 32215 | 13.23% | 2017-06-30 |
| SEI Small Cap Growth A (SIMT) | 187144 | 0.14% | -30000 | -13.82% | 2018-08-31 |
| Vanguard Health Care ETF | 244804 | 0.19% | 2072 | 0.85% | 2018-07-31 |
| Schwab Small Cap Index | 234500 | 0.18% | 19200 | 8.92% | 2018-07-31 |
| The Vanguard Russell 2000 Growth Index | 221356 | 0.17% | 5710 | 2.65% | 2018-07-31 |
| Mutual of America Small Cap Value | 382561 | 0.29% | -- | -- | 2018-03-31 |
| BlackRock Extended Equity Market K | 218113 | 0.17% | 80221 | 58.18% | 2018-06-30 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 193040 | 0.15% | 31046 | 19.16% | 2018-06-30 |
| BlackRock Russell 2000 | 172223 | 0.13% | 18801 | 12.25% | 2018-06-30 |
| TIAA-CREF Small-Cap Equity Instl | 831700 | 0.63% | -- | -- | 2018-04-30 |
| JNL/Invesco Small Cap Growth B | 1226249 | 1.05% | -66787 | -5.17% | 2017-12-31 |
| Met Invt Ser Invesco Small Cap Gr A | 824257 | 0.71% | -91208 | -9.96% | 2017-12-31 |
| Invesco Small Cap Growth A | 1879430 | 1.62% | -115075 | -5.77% | 2017-12-31 |
| BlackRock Value Opportunities Instl | 569285 | 0.49% | -25548 | -4.29% | 2017-09-30 |
| Lord Abbett Micro Cap Growth I | 191873 | 0.17% | -2241 | -1.15% | 2017-11-30 |
| Meridian Contrarian Legacy | 1142477 | 0.98% | -130000 | -10.22% | 2017-09-30 |
| Pru Ret SA/Invesco Small Cap Gr Strat SP | 139626 | 0.12% | 3174 | 2.33% | 2017-09-30 |
| Strategic Advisers | 489075 | 0.42% | 8095 | 1.68% | 2017-08-31 |
| BlackRock Master Value Opportunities LLC | 303346 | 0.26% | -15925 | -4.99% | 2017-11-30 |
| BlackRock Global SmallCap Inv A | 316830 | 0.27% | -242880 | -43.39% | 2017-10-31 |
| AXA/Lord Abbett Micro Cap K | 178463 | 0.19% | -- | -- | 2016-11-30 |
| Lord Abbett Developing Growth A | 1135128 | 1.22% | -1973965 | -63.49% | 2016-12-31 |
| Mutual of America Small Cap Growth | 168161 | 0.18% | 33890 | 25.24% | 2016-09-30 |
| VP Partners Small Cap Growth 2 | 455803 | 0.49% | 153347 | 50.70% | 2016-12-31 |
| Lord Abbett Growth Leaders A | 294004 | 0.32% | -433806 | -59.60% | 2016-12-31 |
| AMG Managers Emerging Opps Svc | 112153 | 0.12% | 17359 | 18.31% | 2016-10-31 |
| BlackRock Glb Global SmallCap Fund | 419402 | 0.60% | -27829 | -6.20% | 2015-07-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 246585 | 0.30% | -- | -- | 2015-09-30 |
| BlackRock Value Opportunities V.I. Fund | 175870 | 0.20% | 9752 | 5.90% | 2015-10-31 |
| Mutual of America Small Cap Growth Fund | 168351 | 0.20% | -- | -- | 2015-06-30 |
| BlackRock Global Small Cap Fund | 144246 | 0.20% | -11720 | -7.50% | 2015-10-31 |
| iShares Russell 2000 (AU) | 960756 | 1.80% | -1212 | -0.10% | 2015-11-19 |
| CREF Stock Account | 166732 | 0.20% | -- | -- | 2015-09-30 |
| John F. Milligan | John F. Milligan is on the board of Pacific Biosciences of California, Inc., Biotechnology Innovation Organization and Ohio Wesleyan University. Dr. Milligan previously held the position of President, Chief Executive Officer & Director at Gilead Sciences, Inc. and President at Pharmasset, Inc. (a subsidiary of Gilead Sciences, Inc.) and Director-Project Management at Hoffmann-La Roche, Inc. Dr. Milligan received a doctorate from the University of Illinois and an undergraduate degree from Ohio Wesleyan University. |
|---|---|
| Marshall L. Mohr | Presently, Marshall L. Mohr holds the position of Chief Financial Officer & Executive Vice President of Intuitive Surgical, Inc. He is also on the board of Plantronics, Inc., Pacific Biosciences of California, Inc. and Intuitive Surgical Ltd. In his past career Marshall L. Mohr occupied the position of Chief Financial Officer & Vice President for Adaptec, Inc. and Managing Partner at PricewaterhouseCoopers LLP. Mr. Mohr received an undergraduate degree from Western Michigan University. |
| Christian O. Henry | Currently, Christian O. Henry is Chairman for Wave Life Sciences Ltd. Mr. Henry is also on the board of Pacific Biosciences of California, Inc. In his past career he held the position of Vice President-Finance & Controller at Nektar Therapeutics, Chief Commercial Officer & Executive VP for Illumina, Inc., Vice President-Finance & Controller at Affymetrix, Inc., Chief Financial Officer of Tickets.com, Inc., Senior Vice President & General Manager at Genomic Solutions, Inc., General Accounting Manager at Sugen LLC and Senior Accountant at Ernst & Young LLP. Mr. Henry received an undergraduate degree from the University of California San Diego and an MBA from the University of California, Irvine. |
| Kevin P. Corcoran | Kevin P. Corcoran is Senior Vice President-Market Development at Pacific Biosciences of California, Inc. He previously occupied the position of President & Chief Executive Officer at Lynx Therapeutics, Inc. and Vice President & GM-DNA Sequencing Business at Applied Biosystems, Inc. Kevin P. Corcoran received an undergraduate degree from California State University-East Bay. |
| Michael W. Hunkapiller | Michael W. Hunkapiller founded Celera Group. Currently, he holds the position of Executive Chairman, President & CEO at Pacific Biosciences of California, Inc. and General Partner of Alloy Ventures, Inc. Dr. Hunkapiller is also on the board of NuGEN Technologies, Inc., Verinata Health, Inc. and RainDance Technologies, Inc. and Member of National Academy of Engineering. Michael W. Hunkapiller previously occupied the position of President & General Manager at Applied Biosystems, Inc. and Senior Vice President for Applera Corp. Dr. Hunkapiller received an undergraduate degree from Oklahoma Baptist University and a doctorate from California Institute of Technology. |
| Brook H. Byers | Dr. Stephen W. Turner is Chief Technical Officer & Vice President at Pacific Biosciences of California, Inc. and a Member of National Institutes of Health. He received his undergraduate degree from the University of Wisconsin and a doctorate degree from Cornell University. |
| Susan K. Barnes | Currently, Susan K. Barnes is CFO, Principal Accounting Officer & Senior VP at Pacific Biosciences of California, Inc. She is also on the board of The Nueva School. In the past Ms. Barnes was Managing Director at Blum Capital Partners LP and Chief Financial Officer & Managing Director at Richard C. Blum & Associates LP (a subsidiary of Blum Capital Partners LP), Chief Financial Officer & Senior VP-Finance at Intuitive Surgical, Inc., Controller-Macintosh Division at Apple, Inc. and Chief Financial Officer & Vice President of NeXt Software, Inc. (a subsidiary of Apple, Inc.) and Managing Director-Private Equity Group at Jefferies LLC. She received an undergraduate degree from Bryn Mawr College and an MBA from The Wharton School of the University of Pennsylvania. |
| Randall S. Livingston | Randall S. Livingston is Chief Financial Officer & VP-Business Affairs at Stanford University and on the board of 5 other companies. He previously held the position of Director-Corporate Development at Apple, Inc., CFO, Director & Executive Vice President at OpenTV, Inc. and Chief Financial Officer of Taligent, Inc. Mr. Livingston received an undergraduate degree and an MBA from Stanford University and an MBA from Stanford Graduate School of Business. |
| Lucy Shapiro | Founder of Anacor Pharmaceuticals, Inc. and Boragen, Inc., Lucy Shapiro occupies the position of Director & Professor at Beckman Center for Molecular & Genetic Medicine. She is also on the board of Pacific Biosciences of California, Inc. and Member of National Academy of Sciences, Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of American Academy of Microbiology, Professor at Stanford University School of Medicine and Professor at The Cancer Research Foundation. In her past career Dr. Shapiro held the position of Scientific Advisor at Hatteras Venture Partners, Chairman-Microbiology & Immunology Department at College of Physicians & Surgeons of BC and Independent Director at Anacor Pharmaceuticals, Inc. Lucy Shapiro received an undergraduate degree from Brooklyn College and a doctorate from Albert Einstein College of Medicine, Inc. |
| William W. Ericson | William W. Ericson founded Venture Law Group LLP. Currently, Mr. Ericson is General Partner of MDV Management Co. LLC. Mr. Ericson is also Member of Personalized Medicine Coalition and Founding Partner of Wildcat Venture Partners LLC and on the board of 10 other companies. He received a graduate degree from Northwestern University School of Law, an undergraduate degree from Edmund A. Walsh School of Foreign Service and an undergraduate degree from Georgetown University School of Foreign Service In Qatar. |
| Kathy P. Ordo�0�1±ez | Kathy P. Ordo�0�1±ez is a businessperson who founded Celera Diagnostics LLC and who has been the head of 6 different companies. She is on the board of Quidel Corp., Pacific Biosciences of California, Inc. and Advanced Medical Technology Association. In the past Ms. Ordo�0�1±ez held the position of President of Celera Diagnostics LLC, Senior Vice President-Diagnostic Solutions at Quest Diagnostics, Inc. President & Chief Executive Officer at Celera Corp. and President of Celera Group (both are subsidiaries of Quest Diagnostics, Inc.), Non-Executive Chairman & Chief Executive Officer at RainDance Technologies, Inc., President & Chief Executive Officer for Roche Molecular Systems, Inc., President at Roche Diagnostics Corp., Principal at Hoffmann-La Roche, Inc. and Senior Vice President at Applera Corp. She received an MBA from Pace University and an undergraduate degree from Hartwick College. |
| Stephen W. Turner | Founder of Pacific Biosciences of California, Inc., Stephen W. Turner is Chief Technology Officer at this company. He is also Member of National Institutes of Health. Dr. Turner received a doctorate from Cornell University and an undergraduate degree from the University of Wisconsin. |
| Stephen M. Moore | Currently, Stephen M. Moore holds the position of Secretary, Vice President & General Counsel for Pacific Biosciences of California, Inc. He previously held the position of General Counsel for Life Technologies Clinical Services Lab, Inc. and General Counsel of Affymetrix, Inc. Mr. Moore received a graduate degree from the University of California, Davis. |
| James Michael Phillips | Presently, James Michael Phillips occupies the position of Senior Vice President-Research & Development at Pacific Biosciences of California, Inc. In his past career he occupied the position of Principal at Hyland Laboratories, Inc., Director-Research & Development at Applied Biosystems, Inc. and Principal at National Marine Fisheries Service. He received an undergraduate degree from the University of California, Davis. |
| David Botstein | Currently, David Botstein is Chief Scientific Officer of Calico LLC. He is also on the board of Pacific Biosciences of California, Inc. and Impossible Foods, Inc. and Member of Institute of Medicine, Member of National Academy of Sciences and Professor-Emeritus at Princeton University. He previously occupied the position of Vice President-Science at Genentech, Inc. and Chairman-Genetics Department at Stanford University. David Botstein received a doctorate from the University of Michigan and an undergraduate degree from Harvard University. |
| Trevin Rard | Currently, Trevin Rard is Head-Investor Relations of Pacific Biosciences of California, Inc. |
| Trevin Rard | Currently, Trevin Rard is Head-Investor Relations of Pacific Biosciences of California, Inc. |
| Jonas Korlach | Jonas Korlach holds the position of Chief Scientific Officer for Pacific Biosciences of California, Inc. Dr. Korlach received a doctorate and a graduate degree from Cornell University and a graduate degree and an undergraduate degree from Humboldt-Universit�0�1¤t zu Berlin. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论